Evaluation of Lp-PLA2 mass, vitronectin and PAI-1 activity levels in patients with preeclampsia

Abstract

Purpose

The aim of the current study is to determine, correlate and compare the plasma lipoprotein-associated phospholipase A2 (Lp-PLA2), vitronectin (Vn), Plasminogen activator inhibitor-1 (PAI-1) activity and tissue plasminogen activator (t-PA) levels in early-onset preeclampsia, late-onset preeclampsia and in control pregnant women.

Methods

A total of 79 individuals, 30 early-onsets, and 22 late-onset preeclamptic and 27 control pregnant women were included into the scope of this study. Enzyme-linked immunosorbent assay procedure was used to determine the serum Lp-PLA2 and plasma Vn, t-PA antigen and PAI-1 activity levels. Serum C-reactive protein (CRP) levels were measured immunoturbidimetrically in routine clinical chemistry analyser.

Results

In patients with preeclampsia, Lp-PLA2, PAI-1, t-PA, CRP and blood pressures levels were increased (p = 0.000) and correlated with each other. Vn levels were decreased (p = 0.016) but not correlated with other parameters in preeclamptic patients.

Conclusion

We are of the opinion that increased Lp-PLA2 levels may partially contribute to endothelial dysfunction by the progression of inflammation. In addition, increased complex formation with Vn is likely to bring about the increase of PAI-1 activity in patients with preeclampsia. Moreover, increased t-PA and decreased Vn levels may also be the consequences of compensatory mechanisms against disease progression.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    ACOG Committee on Obstetric Practice (2002) ACOG practice bulletin. Diagnosis and management of preeclampsi and eclampsia. Number 33, January 2002. American College of Obsteticians and Gynecologists. Int J Gynaecol Obstet 77(1):67–75

    Article  Google Scholar 

  2. 2.

    Weiss G, Goldsmith LT, Taylor RN, Bellet D, Taylor HS (2009) Inflammation in reproductive disorders. Reprod Sci 16(2):216–229

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. 3.

    Fan P, Liu XH, He GL, Zhang S, Zhang JX, Bai H (2012) Maternal and fetal plasma platelet-activating factor acetylhydrolase activity and distribution in pre-eclampsia. Pediatr Res 72(4):426–431

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Ramma W, Ahmed A (2011) Is inflammation the cause of pre-eclampsia? Biochem Soc Trans 39(6):1619–1627

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. 5.

    Dusse LM, Rios DR, Pinheiro MB, Cooper AJ, Lwaleed BA (2011) Pre-eclampsia: relationship between coagulation, fibrinolysis and inflammation. Clin Chim Acta 412(1–2):17–21

    Article  CAS  PubMed  Google Scholar 

  6. 6.

    Boij R, Svensson J, Nilsson-Ekdahl K, Sandholm K, Lindahl TL, Palonek E, Garle M, Berg G, Ernerudh J, Jenmalm M, Matthiesen L (2012) Biomarkers of coagulation, inflammation, and angiogenesis are independently associated with preeclampsia. Am J Reprod Immunol 68(3):258–270

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Abbate R, Cioni G, Ricci I, Miranda M, Gori AM (2012) Thrombosis and acute coronary syndrome. Thromb Res 129(3):235–240

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    Yang EH, McConnell JP, Lennon RJ, Barsness GW, Pumper G, Hartman SJ, Rihal CS, Lerman LO, Lerman A (2006) Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 26(1):106–111

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, Lerman A (2007) Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 115(21):2715–2721

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Garg PK, McClelland RL, Jenny NS, Criqui M, Liu K, Polak JF, Jorgensen NW, Cushman M (2011) Association of lipoprotein-associated phospholipase A (2) and endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA). Vasc Med 16(4):247–252

    Article  PubMed  Google Scholar 

  11. 11.

    Aso Y (2007) Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 12:2957–2966

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Wikström AK, Nash P, Eriksson UJ, Olovsson MH (2009) Evidence of increased oxidative stress and a change in the plasminogen activator inhibitor (PAI)-1 to PAI-2 ratio in early-onset but not late-onset preeclampsia. Am J Obstet Gynecol 201(6):597.e1–597.e8

    Article  Google Scholar 

  13. 13.

    Ekmekçi OB, Ekmekçi H (2006) Vitronectin in atherosclerotic disease. Clin Chim Acta 368(1–2):77–83

    Article  PubMed  Google Scholar 

  14. 14.

    ACOG Committee on Obstetric Practice (2002) ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 99(1):159–167

    Article  Google Scholar 

  15. 15.

    Greer IA, Dawes J, Johnston TA, Calder AA (1991) Neutrophil activation is confined to the maternal circulation in pregnancy-induced hypertension. Obstet Gynecol 78(1):28–32

    CAS  PubMed  Google Scholar 

  16. 16.

    Lynch AM, Murphy JR, Gibbs RS, Levine RJ, Giclas PC, Salmon JE, Holers VM (2010) The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG 117(4):456–462

    Article  CAS  PubMed  Google Scholar 

  17. 17.

    Szarka A, Rigó J Jr, Lázár L, Beko G, Molvarec A (2010) Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 11:59

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. 18.

    Renckens R, Roelofs JJ, de Waard V, Florquin S, Lijnen HR, Carmeliet P, van der Poll T (2005) The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. J Thromb Haemost 3(5):1018–1025

    Article  CAS  PubMed  Google Scholar 

  19. 19.

    Chappell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, Charnock-Jones DS, Mallet AI, Poston L (2002) A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 187(1):127–136

    Article  PubMed  Google Scholar 

  20. 20.

    Tabak O, Gelisgen R, Uzun H, Kalender B, Balci H, Curgunlu A, Simsek G, Karter Y (2009) Hypertension and hemostatic/fibrinolytic balance disorders. Clin Invest Med 32(6):E285–E292

    CAS  PubMed  Google Scholar 

  21. 21.

    Tanjung MT, Siddik HD, Hariman H, Koh SC (2005) Coagulation and fibrinolysis in preeclampsia and neonates. Clin Appl Thromb Hemost 11(4):467–473

    Article  CAS  PubMed  Google Scholar 

  22. 22.

    Shen J, Ma X, Yi F, Rasul A, Cui M, Ma T (2013) Increased expression levels of vitronectin in the maternal fetal interface of placenta in early-onset severe preeclampsia. Mol Med Rep 7(1):53–58

    CAS  PubMed  Google Scholar 

  23. 23.

    Asch E, Podack E (1990) Vitronectin binds to activated human platelets and plays a role in platelet aggregation. J Clin Invest 85(5):1372–1378

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. 24.

    Mohri H, Ohkubo T (1991) How vitronectin binds to activated glycoprotein IIb-IIIa complex and its function in platelet aggregation. Am J Clin Pathol 96(5):605–609

    CAS  PubMed  Google Scholar 

  25. 25.

    Reheman A, Gross P, Yang H, Chen P, Allen D, Leytin V, Freedman J, Ni H (2005) Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost 3(5):875–883

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This study was supported by Istanbul University, Scientific Research Projects Unit (Project Number: BYP-20082).

Conflict of interest

None.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Hakan Ekmekçi.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Balcı Ekmekçi, Ö., Ekmekçi, H., Güngör, Z. et al. Evaluation of Lp-PLA2 mass, vitronectin and PAI-1 activity levels in patients with preeclampsia. Arch Gynecol Obstet 292, 53–58 (2015). https://doi.org/10.1007/s00404-014-3601-1

Download citation

Keywords

  • Preeclampsia
  • Lp-PLA2
  • PAI-1
  • T-PA
  • Vitronectin
  • Endothelial dysfunction